Loredana G. Farilla, M.D.

Curriculum Vitae

11 Upland Road
Medford, MA 02155
(781)-258-2922
farillamerkel@yahoo.com

OBJECTIVE

To obtain a position in a clinical research setting with focus on diabetes management and prevention.

PROFESSIONAL SUMMARY

- Medical Doctor specialized in Endocrinology, Metabolism, and Diabetes with clinical experience working as Endocrinologist in Rome, Italy.

- Research Scientist with over several years of experience in diabetes basic research. Highly skilled in laboratory management, and project planning.

- Published authority in peer reviewed journals. Fluent in English and Italian. Permanent U.S. resident in the process of acquiring the U.S. citizenship.

EDUCATION

- Clinical Research Associate Certification 11/2008
Medical Research Management Inc.

- Fellowship program in Endocrinology, Metabolism and Diabetes, Magna Cum Laude 10/1993-11/1998
University of Rome School of Medicine, 2nd Clinica Medica, Rome, Italy

- Doctor of Medicine and Surgery: Magna cum Laude 11/1986-11/1992
University of Rome School of Medicine, Rome, Italy.

TRAININGS AND CERTIFICATIONS

- Fundamentals of clinical research and drug research development. 11/2008
Medical Research Management Inc.

EMPLOYMENT HISTORY

- Massachusetts General Hospital, Boston, MA — 08/2009-08/2010
Clinical Research Fellow in Nutritional Metabolism: clinical research on pediatric obesity.

- Children's Hospital, Department of Endocrinology, Boston, MA — 02/2007-07/2009
Research Fellow in Pediatrics: stem cell research.

- Amgen Inc. Department of Protein Science, Thousand Oaks, CA — 12/2003-12/2004
Research Scientist: protein science research.

- Cedars-Sinai Medical center, Los Angeles, CA — 06/2001-10/2003
Research Scientist: type II diabetes basic research.

- Cedars-Sinai Medical center, Los Angeles, CA: — 12/1998-06/2001
Postdoctoral Research Fellow: type I diabetes basic research in collaboration with the Barbara Davis Center, Denver, Colorado.

- "Umberto I Hospital", Rome, Italy: — 11/1993-11/1998
Fellowship program in Endocrinology, Metabolism, and Diabetes.

- IRBM-Merck laboratories, Pomezia, Italy — 07/1995-07/1997
Visiting Scientist: type I diabetes basic research.

PROFESSIONAL ASSOCIATIONS

- University of Rome, School of Medicine, Rome, Italy. — 1986-1998

- Harvard Medical School Boston, Massachusetts. — 2007-present

- MIT (Massachusetts Institute of Technology) Boston, Massachusetts. — 2009-present

PUBLICATIONS

1. Breault DT, Min IM, Carlone DL, Farilla LG, Ambruzs DM, Henderson DE, Algra S, Montgomery RK, Wagers AJ, Hole N. Generation of mTert-GFP mice as a model to identify and study tissue progenitor cells. *PNAS*, 105(30):10420-10425, 2008.

2. Noushmehr H, D'Amico E, Farilla L, Hui H, Wawrowsky KA, Mlynarski W, Doria A, Abumrad NA, Perfetti R. Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion. *Diabetes*, 54(2):472-81, 2005.

3. Urusova IA, Farilla L, Hui H, D'Amico E, Perfetti R. GLP-1 inhibition of pancreatic islet cell apoptosis. *Trends Endocrinol Metab*., 15(1):27-33, 2004.

4. Bulotta A, Farilla L, Hui H, Perfetti R. The role of GLP-1 in the regulation of islet cell mass. *Cell Biochem Biophys*., 40(3 Suppl):65-78, 2004.

5. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology*, 144(12):5149-58, 2003.

6. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R. Glucagon-like peptide-1 promotes islets cell growth and inhibits apoptosis in Zucker Diabetic Rats. *Endocrinology*, 143(11):4397-4408, 2002.

7. Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of Glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. *European Journal of Endocrinology*, 146(6):863-9, 2002.

8. Farilla L, Tiberti C, Luzzago A, Yu L, Eisenbarth GS, Cortese R, Dotta F, Di Mario U. Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512 BDC dominant autoantigen epitopes. *European Journal of Immunology*, 32(5):1420-7, 2002.

9. Pichurin P, Yan XM, Farilla L, Guo J, Chazenbalk GD, Rapoport B, McLachlan SM. Naked TSH receptor DNA vaccination: A TH1 T cell response in which interferon-gamma production, rather than antibody, dominates the immune response in mice. *Endocrinology*, 142(8):3530-3536, 2001.

10. Xiong Z, Farilla L, Guo J, McLachlan S, Rapoport B. Does the autoantibodies immunodominant region on thyroid peroxidase include amino acid residues 742-771? *Thyroid*, 11(3):227-23, 2001.

11. Farilla L, Dotta F, Di Mario U, Rapoport B, McLachlan SM. Presence of interleukin 4 or interleukin 10, but not both cytokines, in pancreatic tissue of two patients with recently diagnosed diabetes mellitus type 1. *Autoimmunity*, 32(3):161-166, 2000.

12. Cilio CM, Bosco S, Moretti C, Farilla L, Savignoni F, Colarizi P, Multari G, Di Mario U, Bucci G, Dotta F. Congenital autoimmune diabetes Mellitus. *New Engl. J. Med*, 342(20):1529-1531, 2000.

13. Mennuni C, Santini C, Lazzaro D, Dotta F, Farilla L, Fierabracci A, Bottazzo GF, Di Mario U, Cortese R, Luzzago A. Identification of a novel type 1 diabetic-specific epitope by screening phage libraries with sera from pre-diabetic patients. *J. Mol. Biol.*, 268(3): 599-606, 1997.

14. Misasi R, Dionisi S, Farilla L, Carabba B, Lenti L, Di Mario U, Dotta F. Gangliosides in autoimmune diabetes. *Diab. Met. Rev*., 13(3):163-179, 1997.

15. Dotta F, Dionisi S, Farilla L, Di Mario U. The use of immunological markers in IDDM after more than 20 yeras from ICA description. *Diabetes Metab. Rev*. 12(2):121-6, 1996

16. Mennuni C, Santini C, Dotta F, Farilla L, Di Mario U, Fierabracci A, Bottazzo G, Cortese R, Luzzago A. Selection of phage-displayed peptides mimicking type 1 diabetes-specific epitopes. *J. Autoimmunity*, 9(3):431-436, 1996.

17. Dotta F, Dionisi S, Misasi R, Tiberti C, Anastasi E, Carabba B, Farilla L, Di Mario U. Ganglioside antigens in autoimmune diabetes. *Diab. Nutr. Metab.,* 9:215-220, 1996.

18. Dotta F, Dionisi S, Farilla L, Di Mario U. Prediction of Type 1 diabetes 20 years after the discovery of cytoplasmic ICA. *Diab. Met. Rev.* 12:121-126, 1996.

19. Dionisi S, Sentimentale A, Farilla L, Carabba B, Di Mario U, Dotta F. Gli autoanticorpi diretti contro il ganglioside pancreatico GM2-1 nel topo NOD appartengono alla sottoclasse IgG1. [Autoantibodies Against GM2-1 Ganglioside in NOD Mice Belong to the IgG-1 Subclass]. *Atti del X Congresso Nazionale A.M.D.:* 355-359, 1995.

20. Farilla L, Dionisi S, Carabba B, Previti M, Sentimentale A, Lenti L, Di Mario U, Dotta F. Ganglioside insulare GM2-1: identificazione di una nuova struttura glicolipidica coinvolta nell'autoimmunità beta cellulare. [Islet Ganglioside GM2-1 Identification of a New Glycolipid Molecule Involved in Beta-Cellular Autoimmunity]. *Atti del X Congresso Nazionale A.M.D.:* 351-354, 1995.

21. Sentimentale A, Tiberti C, Dionisi S, Farilla L, Torresi P, Andreani D, Di Mario U, Falorni A, Lernmark A, Dotta F. Il diabete di tipo 1 quale malattia autoimmuneneuroendocrina. [Type-1 Diabetes as a Neuroendocrine Autoimmune Disease]. A*tti del X Congresso Nazionale A.M.D.:* 345-349, 1995.